Medical devices manufacturer Prollenium Medical Technologies has opened its new dermal filler manufacturing facility for tissue reconstruction in Canada.
The automated syringe manufacturing and packaging line of viscous gels for implantation facility employs a fully automated process in a clean room environment. Sterilization, packaging and quality control take place in-house.
According to the company, the site is ISO 13485 registered as well as Health Canada and CE approved.
Prollenium chief executive Ario Khoshbin said, "This new facility now offers a much more proactive opportunity for us to meet changes in the marketplace."
The new location is expected to yield a capacity of more than two million syringes a year.